Q-omics provides the consensus-scored COIL profile across patient tissues and cancer cell-line models. COIL expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, COIL is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, COIL protein abundance shows 23,729 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, HNSC, and LSCC as cancer lineages where COIL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COIL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COIL survival associations across molecular data types. COIL RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COIL RNA expression–survival associations across cancer types. High COIL expression shows unfavorable associations in KIRP, LIHC, ACC and KICH, but favorable associations in UCS and KIRC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for COIL RNA expression.
This table summarizes COIL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for COIL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COIL shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LIHC, KIRP and LUAD. The HNSC box plot shows higher COIL RNA expression in tumor versus normal tissue (log2 FC = +0.779, t-test p < 0.001).
This table shows molecular features associated with COIL in patient tissues and cancer cell lines. In patient samples, COIL shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, COIL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
